Download presentation
Presentation is loading. Please wait.
Published byAmie Hart Modified over 9 years ago
1
Tandem Mass Spectrometry Newborn Screening Quality Assurance and Control Instrument and Method Validation Gary Hoffman Wisconsin Newborn Screening Laboratory State Laboratory of Hygiene Madison WI
2
Training Issues Instrument vendor site training - Instrument operation - Instrument troubleshooting Visit other MS/MS laboratories - 20 + MS/MS testing programs - spit equally between vendors APHL and NNSGRC sponsored courses - Baylor Institute of Metabolic Diseases - Duke Medical Center Write standard operating procedure Develop training and competency logs
3
Instrument Performance Issues Mass Calibration – Establish operating range of instrument Typical mass range 59 mu to 1800 mu – Materials used Polypropylene (PPG) NaI / RbI solution
4
Instrument Performance Issues Unit Resolution – MS/MS unit resolution voltages 0.7 of a mass unit at 50% peak height – Frequency Initial instrument set up Schedules vary
5
Instrument Performance Issues Sample loop size – Provides consistent injection volumes – Best results when loop size equals injection volume. – Typical loop sizes used 10 - 30 µL Probe rinses – Minimize Carryover
6
Instrument Performance Issues Detection Optimization – Front End (ESI, cone, orifice, ring) voltages. Allows analyte ionization Minimize fragmentation – Collision chamber, 2 nd quadrapole, detector voltages Maximize output response detector voltage decrease needs adjustment.
7
Instrument Performance Issues State files – Mass calibration – Voltages for each experiment (precursor ion, neutral loss, MRM) Method files – Scan Parameters – Analytical run time Help minimize carryover Long enough to return to baseline Typical run times: 1.5 to 3.0 minutes/specimen
8
Instrument Performance Issues Data Reduction Software – Calibration Table Analyte & internal standard masses – Designates which masses will be calculated from with internal standard – Example: DC8 for C5DC, C10, C10:1, C10:2, C6DC Internal standard concentration Blood spot volume – small changes are significant – 0.2 µL change – 20% change in control results – standard blood spot volume needed
9
Instrument Performance Issues Calibration Table (Cont) Extraction volume – Accounts for specimen dilution – V olume added before extraction is critical – After extraction, exact volume is less important Analyte cut off levels Analyte ratios – Phe/Tyrosine – C8/C10 Internal standard count thresholds
10
Method Validation Issues Establish linearity – Prepare spiked blood spots Six to eight levels – Lowest level: endogenous – Highest level: expected in affected babies Plot observed vs expected results – linearity is the straight part of the line
11
Method Validation Issues Establish intra and inter run precision – Materials Two analyte(s) spike levels – First level: Medical decision level – Second level: 4 X first level
12
Method Validation Issues Intra run precision – extract and prepare a set of blood spots. Minimum of 20 replicate analysis – Analyze in the same run on the same day. – Calculate Coefficient of Variation (CV) Expected coefficient of variation: < 10%.
13
Method Validation Issues Inter run precision – Multiple day analysis – Prepare 2 extracts for each spiked pool daily – Analyze in runs for a minimum of 10 days. – Calculate Coefficient of Variation (CV) Expected coefficient of variation (CV) : 15 – 20%
14
Method Validation Issues Establish Accuracy – Recovery Calculate recovery from intra run precision data – Observed value/expected value X100 – Acceptable recoveries: > 85% – Known disease cases Specimens on disease cases (metabolic clinics) Contact MS/MS colleagues
15
Method Validation Issues Non-Peer Reviewed methods – Direct comparison with established methods Analyze a minimum of 500 specimens by both methods May have to “spike” blood for some analytes Calculate slope and intercept for each analyte – Slopes greater than 0.900 are acceptable
16
Routine Specimen Analysis Analysis of routine blood spots specimens – Test all specimens received Establish a reporting policy – Test limited number of specimens Obtain blinded specimens from MS/MS colleagues Liability issues eliminated
17
Interferences/Contamination Interferences – TPN Amino Acids Acylcarnitines: C5, and C18:2 – Reporting As potential disorder – potentially confusing Unsatisfactory – Request repeat after TPN discontinued – Closely review results
18
Interferences/Contamination Contaminations – Floor wax Leucine interference – Detergent surfactants Baseline increase – Glassware contamination Hemoglobin testing stain
19
Establishing Analyte Cutoffs Pilot Testing – Do a literature search – Contact existing MS/MS programs – Manufacture of instrument or reagents Routine Testing Cutoffs – Analyze several thousand normal specimens – Calculate mean and standard deviation
20
Establishing Analyte Cutoffs Establish Analyte cutoffs Consult metabolic specialist/follow up staff. Typical cutoffs: 3 and 10 sd from mean Compare cutoffs with other MS/MS programs. A balance between false positives/negatives Consider separate ranges for age > 7 days.
21
Quality Control Plan Documents quality control decisions – Imprecision factors Blood spot absorption methodology drift Inconsistent ion flow – Acceptable plate quality control Control results within ± 3 sd Allow some number outside ± 3 sd
22
Quality Control Plan Quality control review – Daily Checked by analyst and supervisor – Monthly Reviewed by Supervisor Long term documentation
23
Quality Control Plan – Repeat individual specimens No masses detected – No sample injected – Electronic errors Abnormal results profiles – Example: C6, C8, C10:1, C8/C10 – Some secondary markers not reported Poor Sensitivity – d-Phe, d-C8, d-Cit below sensitivity threshold – Latitude in decision making – Document decisions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.